Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
about
The clinical application of linagliptin in AsiansComparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic reviewEfficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: subgroup analysis of a randomized clinical trial.Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Iron-catalyzed cascade reaction of 2-aminobenzyl alcohols with benzylamines: synthesis of quinazolines by trapping of ammonia.Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
P2860
Q26781942-64375F09-AC8A-48B6-8588-D4D9C66BA288Q28540671-A6F1CEB2-4494-4195-A903-67C197857ABAQ33785117-1CBACFC6-E93E-4CF9-B5D7-0CF8F51A42CAQ35800419-F2681189-B1A5-4EBD-AB67-3853C2F965ECQ36232782-55F580FA-0F7E-4FB0-B42E-CFB138AA6359Q38258278-175029C3-C97F-46AA-9CDC-FF7C38E45CD9Q38716033-76683E3A-E8A2-4E99-8964-061B63AA84E3Q39870068-6589842B-0110-43DE-A242-330DDD1AF683Q41997013-B2698AFD-1C47-4719-9149-C400E4B40FC3Q47386188-FE6D7EF8-8C7B-4610-9901-37EA508CB126Q48205758-7028DCF9-45F2-471B-B3F7-7228BCF017B4Q51321908-C32F4272-A8C6-4FB6-97B9-1BCCB8A7E9D6
P2860
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Linagliptin provides effective ...... patients with type 2 diabetes.
@en
Linagliptin provides effective ...... patients with type 2 diabetes.
@nl
type
label
Linagliptin provides effective ...... patients with type 2 diabetes.
@en
Linagliptin provides effective ...... patients with type 2 diabetes.
@nl
prefLabel
Linagliptin provides effective ...... patients with type 2 diabetes.
@en
Linagliptin provides effective ...... patients with type 2 diabetes.
@nl
P2093
P2860
P356
P1476
Linagliptin provides effective ...... patients with type 2 diabetes.
@en
P2093
P2860
P304
P356
10.1111/DOM.12110
P577
2013-05-03T00:00:00Z